Vergent Bioscience
$18.7M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Vergent Bioscience is currently valued at $75.0M as of October 20, 2025. The company has raised a total of $56.4M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.33x, Vergent Bioscience has achieved a valuation that is 1.33 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Vergent Bioscience's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Vergent Bioscience Worth in 2025?
As of 2025, Vergent Bioscience is valued at $75.0M, based on the company's Later Stage VC funding round in October 20, 2025. This valuation positions Vergent Bioscience as one of the leading private companies in the sector.
Vergent Bioscience Valuation History
Vergent Bioscience's funding history demonstrates steady growth and investor confidence.
How Vergent Bioscience Valuation is Determined
Private company valuations like Vergent Bioscience's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Vergent Bioscience Valuation FAQs
Is Vergent Bioscience profitable?
Vergent Bioscience has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Vergent Bioscience's valuation compare to competitors?
Vergent Bioscience is valued at $75.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Vergent Bioscience IPO?
Vergent Bioscience has not announced plans for an initial public offering. Until an IPO, investors can access Vergent Bioscience shares through secondary market platforms.